EUCTR2016-002328-10-NL进行中（未招募）1 期
A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects withMucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated ViralVector 8 to Deliver the human ARSB gene to Liver.
FONDAZIONE TELETHO0 个研究点目标入组 10 人开始时间: 2018年11月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Subjects must have a documented biochemical and molecular diagnosis of MPS VI.
- •2.Subjects must be 4 years old or older.
- •3.Subjects should have received Enzyme Replacement Therapy (ERT) for at least 12 months before enrolment, and should continue to receive treatment until 7-14 days before IMP administration.
- •4.Documented informed consent; willingness to adhere to protocol and required long-term follow-up as evidenced by written informed consent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 8
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 3
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Subjects unable or unwilling to meet requirements of the study.
- •2.History of severe anaphylactoid reaction to Naglazyme in subjects
- •receiving ERT that could affect the safety (severe reaction is
- •meant to be an event with respiratory impairment that is lifethreatening).
- •3.Serum AST or ALT above the upper limit of normal range at the
- •baseline evaluations (Baseline 2, -5 days).
- •4. Detectable serum neutralizing antibodies (NAB) against AAV8 vector.
研究者
相似试验
尚未招募
不适用
A Phase I/II Open Label, Dose Escalation, Safety Study in Subjects with Mucopolysaccharidosis type VI (MPS VI) Using Adeno-Associated Viral Vector 8 to Deliver the human ARSB gene to Liver.NL-OMON47624Fondazione Telethon4
进行中（未招募）
1 期
Gene Therapy in patients with Mucopolysaccharidosis diseaseEUCTR2016-002328-10-ITFONDAZIONE TELETHO10
进行中（未招募）
1 期
A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic Strokethrombus in acute ischemic stroke of the middle cerebral arteryMedDRA version: 12.0Level: HLTClassification code 10007948Term: Central nervous system haemorrhages and cerebrovascular accidentsEUCTR2009-012086-66-FRTalecris Biotherapeutics Inc40
进行中（未招募）
1 期
A Phase 1/2a, Open Label, Dose Escalation, Safety Study of Intra-thrombus Plasmin (Human) Administration in Acute, Middle Cerebral Artery, Ischemic StrokeThrombus in acute ischemic stroke of the middle cerebral arteryMedDRA version: 12.0Level: HLTClassification code 10007948Term: Central nervous system haemorrhages and cerebrovascular accidentsEUCTR2009-012086-66-SKTalecris Biotherapeutics Inc75
进行中（未招募）
1 期
Study to test the safety of human plamin on patients suffering from strokeThrombus in acute ischemic stroke of the middle cerebral arteryMedDRA version: 14.1 Level: PT Classification code 10008190 Term: Cerebrovascular accident System Organ Class: 10029205 - Nervous system disordersEUCTR2009-012086-66-GBGrifols Inc40